Well, so think of this particular gene, the one I mentioned that brought me to the U.S., as kind of a microcosm of all things over those years, right? But of course, we were doing this at multiple loci. But the problem there was we couldn't do diagnostics or molecular characterization on individuals prior to 1986. We couldn't do it without inference.
So you could take a child with the disease—this is an X-linked disease, so the boys only have one copy—if you ever found out the mutation, you could go and track it in the family and in the mothers, but you couldn't effectively go and—or easily at all—go and look at it in women to ask, might they be carriers of the disease? Okay? So, you know, like finding the mutation was hard. You could only really do it in hemizygosity. You certainly couldn't tackle random individuals. This is the old days, right?
So suddenly, with PCR, we had some tools that we'd built to get there. But the thing we lacked actually was full locus sequence information. Right. We had the cDNA. You know, we'd cloned the gene, or others had cloned the gene. We had the gene. We didn't have the flanking things flanking the exons.
So a milestone project was undertaken, of which I was not a central part of, but I was in the peanut gallery too. So Dr. Caskey will tell you, when you talk with him I'm sure, about his work with Wilhelm and Sorge at EMBL on the first fluorescent automated sequencer that was built by the Pharmacia Corporation, the ELF sequencer. And so Wilhelm wanted to demonstrate its efficacy.
So, in Houston, we had the large genomic clones with the HPRT 44 kb locus in it. So, that was an ideal candidate for a big piece of DNA. I mean, 40 kilobases, huge, for us to sequence with an automated method. Right. So, the production of shotgun libraries was carried out in my lab with my colleagues, and those were—my technician took them to Germany and stayed there and worked with Wilhelm's group generating the raw sequence.
Now, this automated sequencer actually needed individuals to write down the bases as they came past the detector, so there was—a lot of the automation wasn't really there. You know, we didn't have computers really. I mean, we just had fancy word processors at that time, so you know the computer era.
So an interesting development in that project was sequencing both ends of a subclone. Right. Which is a standard thing today. So there's a good story about that, which is that that came about in that project, was the first time it was used, and used to anchor reads in assemblies. And the reason it came about is because the shotgun libraries were made in M13, which is a single-stranded—produces single-stranded virions, which you can then get a very pure DNA prep that's very good for priming and extending for sequencing.
Now, after using a bunch of these clones from a library, the library was exhausted. There were no new clones to go to, but more raw sequence coverage was needed to get a shotgun assembly of this 44 kilobases. So the group decided they'd have to go back to the bacteria that secrete the single-stranded virus and extract the double-stranded form and use the other end just to get more sequence coverage.
And then when they did that, and they built the assemblies, they said, well, you know, these things ought to go opposite each other. And that was the sequence map gap methods, which are in some of the early books you can find.
So anyway, that project was a fabulous success, gave us the sequence that flanked the exons in that gene, and we were able to construct PCR primers for each exon, build a multiplex reaction, and then do the automated sequencing across them to look for any positions that in females would be heterozygous that could give risk to a child, a boy, if he inherited the one copy with the mutation.
So all that evolved over the period of beginning of 1986 to probably 1990 or 1989. So that was sequencing-based development, right? And as you know, most of the discussion there was not really applied sequencing. There was a little bit of sequencing technology stuff, like which sequencing things should we use. But a lot of it was about BAC, YAC cloning, and, you know, other kind of whole genome-y things. And then there was this disease discovery angle that was sort of going on that was finding new genes around CF and muscular dystrophy and neurofibromatosis. And then all of those other loci.